Aura Biosciences (AURA) EBITDA (2020 - 2026)

Aura Biosciences has reported EBITDA for 7 years, with the latest figure at -$33.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 22.25% year-over-year to -$33.8 million; the trailing twelve-month figure through Mar 2026 stood at -$112.7 million (down 19.13% YoY), and the FY2025 full-year result was -$106.6 million, down 22.2% from the prior year.
• EBITDA for Q1 2026 stood at -$33.8 million, down from -$25.7 million in the prior quarter.
• The five-year high for EBITDA was -$12.8 million in Q1 2022, with the low at -$33.8 million in Q1 2026.
• Historically, EBITDA has averaged -$21.3 million across 5 years, with a median of -$20.3 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA plunged 80.13% — and 2025, when it rose 1.71%.
• Aura Biosciences' EBITDA stood at -$16.5 million in 2022, then plunged by 30.17% to -$21.5 million in 2023, then slipped by 22.0% to -$26.2 million in 2024, then climbed by 1.71% to -$25.7 million in 2025, then slumped by 31.33% to -$33.8 million in 2026.
• The last three EBITDA figures came in at -$33.8 million (Q1 2026), -$25.7 million (Q4 2025), and -$26.1 million (Q3 2025), per Business Quant data.